サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1762712

高インスリン血症 低血糖治療の世界市場に関する洞察、2031年までの予測

Global Hyperinsulinemia Hypoglycaemia Treatment Market Insights, Forecast to 2031

出版日
発行
QYResearch
ページ情報
英文 140 Pages
納期
2～3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.09円
高インスリン血症 低血糖治療の世界市場に関する洞察、2031年までの予測
出版日: 2025年07月07日
発行: QYResearch
ページ情報: 英文 140 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、高インスリン血症 低血糖治療 (Hyperinsulinemia Hypoglycaemia Treatment) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析：タイプ別
    • 世界の高インスリン血症 低血糖治療の市場規模成長率：タイプ別: 2020 VS 2024 VS 2031
    • Insulin Analogs
    • Diazoxide
    • Somatostatin Analogs
    • Other
  • 市場：用途別
    • 世界の高インスリン血症 低血糖治療の市場シェア：用途別: 2020 VS 2024 VS 2031
    • Hospital
    • Clinic
    • Other
  • 前提条件と制限
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界の高インスリン血症 低血糖治療の市場展望 (2020-2031)
  • 世界の高インスリン血症 低血糖治療の市場成長トレンド：地域別
    • 世界の高インスリン血症 低血糖治療 市場規模：地域別: 2020 VS 2024 VS 2031
    • 高インスリン血症 低血糖治療 市場規模：地域別 (2020-2031)
  • 高インスリン血症 低血糖治療 市場動向
    • 高インスリン血症 低血糖治療 業界動向
    • 高インスリン血症 低血糖治療 市場の促進要因
    • 高インスリン血症 低血糖治療 市場の課題
    • 高インスリン血症 低血糖治療 市場の抑制要因

第3章 競合情勢：主要企業別

  • 世界の収益 高インスリン血症 低血糖治療 ：競合別
    • 世界の高インスリン血症 低血糖治療の収益：企業別 (2020-2025)
    • 世界の高インスリン血症 低血糖治療の収益シェア：企業別 (2020-2025)
  • 世界の高インスリン血症 低血糖治療の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 世界の主要企業 高インスリン血症 低血糖治療, 売上高ランキング, 2023 VS 2024 VS 2025
  • 世界の市場集中度
    • 世界の高インスリン血症 低血糖治療 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業： 高インスリン血症 低血糖治療 収益 2024年
  • 世界の主要企業 高インスリン血症 低血糖治療 本社 および提供地域
  • 世界の主要企業 高インスリン血症 低血糖治療, 製品およびアプリケーション
  • 世界の主要企業 高インスリン血症 低血糖治療, 業界参入時期
  • M&A, 拡張計画

第4章 内訳データ：タイプ別

  • 世界の高インスリン血症 低血糖治療の市場規模実績：タイプ別 (2020-2025)
  • 世界の高インスリン血症 低血糖治療の市場規模予測：タイプ別 (2026-2031)

第5章 内訳データ：用途別

  • 世界の高インスリン血症 低血糖治療の市場規模実績：用途別 (2020-2025)
  • 世界の高インスリン血症 低血糖治療の市場規模予測：用途別 (2026-2031)

第6章 北米

  • 北米の高インスリン血症 低血糖治療 市場規模 (2020-2031)
  • 北米の市場規模：タイプ別
    • 北米の高インスリン血症 低血糖治療 市場規模：タイプ別 (2020-2031)
    • 北米の高インスリン血症 低血糖治療の市場シェア：タイプ別 (2020-2031)
  • 北米の市場規模：用途別
    • 北米の高インスリン血症 低血糖治療 市場規模：用途別 (2020-2031)
    • 北米の高インスリン血症 低血糖治療の市場シェア：用途別 (2020-2031)
  • 北米の市場規模：国別
    • 北米の高インスリン血症 低血糖治療 市場規模：国別: 2020 VS 2024 VS 2031
    • 北米の高インスリン血症 低血糖治療 市場規模：国別 (2020-2031)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の高インスリン血症 低血糖治療 市場規模 (2020-2031)
  • 欧州の市場規模：タイプ別
    • 欧州の高インスリン血症 低血糖治療 市場規模：タイプ別 (2020-2031)
    • 欧州の高インスリン血症 低血糖治療の市場シェア：タイプ別 (2020-2031)
  • 欧州の市場規模：用途別
    • 欧州の高インスリン血症 低血糖治療 市場規模：用途別 (2020-2031)
    • 欧州の高インスリン血症 低血糖治療の市場シェア：用途別 (2020-2031)
  • 欧州の市場規模：国別
    • 欧州の高インスリン血症 低血糖治療 市場規模：国別: 2020 VS 2024 VS 2031
    • 欧州の高インスリン血症 低血糖治療 市場規模：国別 (2020-2025)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧

第8章 中国

  • 中国の高インスリン血症 低血糖治療 市場規模 (2020-2031)
  • 中国の市場規模：タイプ別
    • 中国の高インスリン血症 低血糖治療 市場規模：タイプ別 (2020-2031)
    • 中国の高インスリン血症 低血糖治療の市場シェア：タイプ別 (2020-2031)
  • 中国の市場規模：用途別
    • 中国の高インスリン血症 低血糖治療 市場規模：用途別 (2020-2031)
    • 中国の高インスリン血症 低血糖治療の市場シェア：用途別 (2020-2031)

第9章 アジア（中国を除く）

  • アジア地域 高インスリン血症 低血糖治療 市場規模 (2020-2031)
  • アジア地域 市場規模：タイプ別
    • アジア地域 高インスリン血症 低血糖治療 市場規模：タイプ別 (2020-2031)
    • アジア地域 高インスリン血症 低血糖治療の市場シェア：タイプ別 (2020-2031)
  • アジア地域 市場規模：用途別
    • アジア地域 高インスリン血症 低血糖治療 市場規模：用途別 (2020-2031)
    • アジア地域 高インスリン血症 低血糖治療の市場シェア：用途別 (2020-2031)
  • アジア地域 市場規模：地域別
    • アジア地域 高インスリン血症 低血糖治療 市場規模：地域別: 2020 VS 2024 VS 2031
    • アジア地域 高インスリン血症 低血糖治療 市場規模：地域別 (2020-2031)
    • 日本
    • 韓国
    • 台湾
    • 東南アジア
    • インド
    • オーストラリア

第10章 中近東・アフリカ・中南米

  • 中近東・アフリカ・中南米 高インスリン血症 低血糖治療 市場規模 (2020-2031)
  • 中近東・アフリカ・中南米 市場規模：タイプ別
    • 中近東・アフリカ・中南米 高インスリン血症 低血糖治療 市場規模：タイプ別 (2020-2031)
    • 中近東・アフリカ・中南米 高インスリン血症 低血糖治療の市場シェア：タイプ別 (2020-2031)
  • 中近東・アフリカ・中南米 市場規模：用途別
    • 中近東・アフリカ・中南米 高インスリン血症 低血糖治療 市場規模：用途別 (2020-2031)
    • 中近東・アフリカ・中南米の市場シェア：用途別 (2020-2031)
  • 中近東・アフリカ・中南米 市場規模：国別
    • 中近東・アフリカ・中南米 高インスリン血症 低血糖治療 市場規模：国別: 2020 VS 2024 VS 2031
    • 中近東・アフリカ・中南米 高インスリン血症 低血糖治療 市場規模：国別 (2020-2031)
    • ブラジル
    • メキシコ
    • トルコ
    • サウジアラビア
    • イスラエル
    • 湾岸協力理事会諸国

第11章 主要企業のプロファイル

  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Mallinckrodt Pharmaceuticals
  • Ipsen Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Wockhardt Limited
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Mylan N.V.
  • Accord Healthcare Ltd.
  • Oramed Pharmaceuticals Inc.

第12章 アナリストによる分析/結論

第13章 付録

図表

List of Tables

Table 1. Global Hyperinsulinemia Hypoglycaemia Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Insulin Analogs

Table 3. Key Players of Diazoxide

Table 4. Key Players of Somatostatin Analogs

Table 5. Key Players of Other

Table 6. Global Hyperinsulinemia Hypoglycaemia Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Hyperinsulinemia Hypoglycaemia Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Market Size by Region (2020-2031) & (US$ Million)

Table 9. Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Region (2020-2031)

Table 10. Market Trends

Table 11. Market Drivers

Table 12. Market Challenges

Table 13. Market Restraints

Table 14. Global Hyperinsulinemia Hypoglycaemia Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Players (2020-2025)

Table 16. Global Top Hyperinsulinemia Hypoglycaemia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperinsulinemia Hypoglycaemia Treatment as of 2024)

Table 17. Global Hyperinsulinemia Hypoglycaemia Treatment Industry Ranking 2023 VS 2024

Table 18. Global 5 Largest Players Market Share by Hyperinsulinemia Hypoglycaemia Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Hyperinsulinemia Hypoglycaemia Treatment, Headquarters and Area Served

Table 20. Global Key Players of Hyperinsulinemia Hypoglycaemia Treatment, Product and Application

Table 21. Global Key Players of Hyperinsulinemia Hypoglycaemia Treatment, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Hyperinsulinemia Hypoglycaemia Treatment Revenue Market Share by Type (2020-2025)

Table 25. Global Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Hyperinsulinemia Hypoglycaemia Treatment Revenue Market Share by Type (2026-2031)

Table 27. Global Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Hyperinsulinemia Hypoglycaemia Treatment Revenue Market Share by Application (2020-2025)

Table 29. Global Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Hyperinsulinemia Hypoglycaemia Treatment Revenue Market Share by Application (2026-2031)

Table 31. North America Market Size by Type (2020-2031) & (US$ Million)

Table 32. North America Market Size by Application (2020-2031) & (US$ Million)

Table 33. North America Hyperinsulinemia Hypoglycaemia Treatment Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Market Size by Country (2020-2031) & (US$ Million)

Table 35. Europe Market Size by Type (2020-2031) & (US$ Million)

Table 36. Europe Market Size by Application (2020-2031) & (US$ Million)

Table 37. Europe Hyperinsulinemia Hypoglycaemia Treatment Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Market Size by Country (2020-2025) & (US$ Million)

Table 39. China Market Size by Type (2020-2031) & (US$ Million)

Table 40. China Market Size by Application (2020-2031) & (US$ Million)

Table 41. Asia Market Size by Type (2020-2031) & (US$ Million)

Table 42. Asia Market Size by Application (2020-2025) & (US$ Million)

Table 43. Asia Hyperinsulinemia Hypoglycaemia Treatment Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031

Table 44. Asia Market Size by Region (2020-2031) & (US$ Million)

Table 45. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million)

Table 46. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million)

Table 47. Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million)

Table 49. Eli Lilly and Company Company Details

Table 50. Eli Lilly and Company Business Overview

Table 51. Eli Lilly and Company Hyperinsulinemia Hypoglycaemia Treatment Product

Table 52. Eli Lilly and Company Revenue (2020-2025) & (US$ Million)

Table 53. Eli Lilly and Company Recent Development

Table 54. Novo Nordisk A/S Company Details

Table 55. Novo Nordisk A/S Business Overview

Table 56. Novo Nordisk A/S Hyperinsulinemia Hypoglycaemia Treatment Product

Table 57. Novo Nordisk A/S Revenue (2020-2025) & (US$ Million)

Table 58. Novo Nordisk A/S Recent Development

Table 59. Sanofi S.A. Company Details

Table 60. Sanofi S.A. Business Overview

Table 61. Sanofi S.A. Hyperinsulinemia Hypoglycaemia Treatment Product

Table 62. Sanofi S.A. Revenue (2020-2025) & (US$ Million)

Table 63. Sanofi S.A. Recent Development

Table 64. Mallinckrodt Pharmaceuticals Company Details

Table 65. Mallinckrodt Pharmaceuticals Business Overview

Table 66. Mallinckrodt Pharmaceuticals Hyperinsulinemia Hypoglycaemia Treatment Product

Table 67. Mallinckrodt Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 68. Mallinckrodt Pharmaceuticals Recent Development

Table 69. Ipsen Pharma Company Details

Table 70. Ipsen Pharma Business Overview

Table 71. Ipsen Pharma Hyperinsulinemia Hypoglycaemia Treatment Product

Table 72. Ipsen Pharma Revenue (2020-2025) & (US$ Million)

Table 73. Ipsen Pharma Recent Development

Table 74. Teva Pharmaceutical Industries Ltd. Company Details

Table 75. Teva Pharmaceutical Industries Ltd. Business Overview

Table 76. Teva Pharmaceutical Industries Ltd. Hyperinsulinemia Hypoglycaemia Treatment Product

Table 77. Teva Pharmaceutical Industries Ltd. Revenue (2020-2025) & (US$ Million)

Table 78. Teva Pharmaceutical Industries Ltd. Recent Development

Table 79. Dr. Reddy's Laboratories Ltd. Company Details

Table 80. Dr. Reddy's Laboratories Ltd. Business Overview

Table 81. Dr. Reddy's Laboratories Ltd. Hyperinsulinemia Hypoglycaemia Treatment Product

Table 82. Dr. Reddy's Laboratories Ltd. Revenue (2020-2025) & (US$ Million)

Table 83. Dr. Reddy's Laboratories Ltd. Recent Development

Table 84. Wockhardt Limited Company Details

Table 85. Wockhardt Limited Business Overview

Table 86. Wockhardt Limited Hyperinsulinemia Hypoglycaemia Treatment Product

Table 87. Wockhardt Limited Revenue (2020-2025) & (US$ Million)

Table 88. Wockhardt Limited Recent Development

Table 89. Baxter International Inc. Company Details

Table 90. Baxter International Inc. Business Overview

Table 91. Baxter International Inc. Hyperinsulinemia Hypoglycaemia Treatment Product

Table 92. Baxter International Inc. Revenue (2020-2025) & (US$ Million)

Table 93. Baxter International Inc. Recent Development

Table 94. Fresenius Kabi AG Company Details

Table 95. Fresenius Kabi AG Business Overview

Table 96. Fresenius Kabi AG Hyperinsulinemia Hypoglycaemia Treatment Product

Table 97. Fresenius Kabi AG Revenue (2020-2025) & (US$ Million)

Table 98. Fresenius Kabi AG Recent Development

Table 99. Mylan N.V. Company Details

Table 100. Mylan N.V. Business Overview

Table 101. Mylan N.V. Hyperinsulinemia Hypoglycaemia Treatment Product

Table 102. Mylan N.V. Revenue (2020-2025) & (US$ Million)

Table 103. Mylan N.V. Recent Development

Table 104. Accord Healthcare Ltd. Company Details

Table 105. Accord Healthcare Ltd. Business Overview

Table 106. Accord Healthcare Ltd. Hyperinsulinemia Hypoglycaemia Treatment Product

Table 107. Accord Healthcare Ltd. Revenue (2020-2025) & (US$ Million)

Table 108. Accord Healthcare Ltd. Recent Development

Table 109. Oramed Pharmaceuticals Inc. Company Details

Table 110. Oramed Pharmaceuticals Inc. Business Overview

Table 111. Oramed Pharmaceuticals Inc. Hyperinsulinemia Hypoglycaemia Treatment Product

Table 112. Oramed Pharmaceuticals Inc. Revenue (2020-2025) & (US$ Million)

Table 113. Oramed Pharmaceuticals Inc. Recent Development

Table 114. Research Programs/Design for This Report

Table 115. Key Data Information from Secondary Sources

Table 116. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Hyperinsulinemia Hypoglycaemia Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 2. Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type: 2024 VS 2031

Figure 3. Insulin Analogs Features

Figure 4. Diazoxide Features

Figure 5. Somatostatin Analogs Features

Figure 6. Other Features

Figure 7. Global Hyperinsulinemia Hypoglycaemia Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 8. Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application: 2024 VS 2031

Figure 9. Hospital Case Studies

Figure 10. Clinic Case Studies

Figure 11. Other Case Studies

Figure 12. Hyperinsulinemia Hypoglycaemia Treatment Report Years Considered

Figure 13. Global Hyperinsulinemia Hypoglycaemia Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Hyperinsulinemia Hypoglycaemia Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Region: 2024 VS 2031

Figure 16. Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Players in 2024

Figure 17. Global Top Hyperinsulinemia Hypoglycaemia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperinsulinemia Hypoglycaemia Treatment as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Hyperinsulinemia Hypoglycaemia Treatment Revenue in 2024

Figure 19. North America Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)

Figure 21. North America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)

Figure 22. North America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Country (2020-2031)

Figure 23. United States Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)

Figure 27. Europe Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)

Figure 28. Europe Hyperinsulinemia Hypoglycaemia Treatment Market Share by Country (2020-2031)

Figure 29. Germany Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. China Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. China Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)

Figure 37. China Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)

Figure 38. Asia Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Asia Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)

Figure 40. Asia Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)

Figure 41. Asia Hyperinsulinemia Hypoglycaemia Treatment Market Share by Region (2020-2031)

Figure 42. Japan Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. South Korea Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. China Taiwan Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Southeast Asia Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. India Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Australia Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)

Figure 50. Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)

Figure 51. Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Country (2020-2031)

Figure 52. Brazil Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Mexico Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Turkey Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. Israel Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 57. GCC Countries Hyperinsulinemia Hypoglycaemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 58. Eli Lilly and Company Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 59. Novo Nordisk A/S Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 60. Sanofi S.A. Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 61. Mallinckrodt Pharmaceuticals Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 62. Ipsen Pharma Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 63. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 64. Dr. Reddy's Laboratories Ltd. Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 65. Wockhardt Limited Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 66. Baxter International Inc. Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 67. Fresenius Kabi AG Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 68. Mylan N.V. Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 69. Accord Healthcare Ltd. Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 70. Oramed Pharmaceuticals Inc. Revenue Growth Rate in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)

Figure 71. Bottom-up and Top-down Approaches for This Report

Figure 72. Data Triangulation

Figure 73. Key Executives Interviewed

目次

This research report focuses on the Hyperinsulinemia Hypoglycaemia Treatment Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Hyperinsulinemia Hypoglycaemia Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
    • 1.2.2 Insulin Analogs
    • 1.2.3 Diazoxide
    • 1.2.4 Somatostatin Analogs
    • 1.2.5 Other
  • 1.3 Market by Application
    • 1.3.1 Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application: 2020 VS 2024 VS 2031
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Other
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Hyperinsulinemia Hypoglycaemia Treatment Market Perspective (2020-2031)
  • 2.2 Global Hyperinsulinemia Hypoglycaemia Treatment Growth Trends by Region
    • 2.2.1 Global Hyperinsulinemia Hypoglycaemia Treatment Market Size by Region: 2020 VS 2024 VS 2031
    • 2.2.2 Hyperinsulinemia Hypoglycaemia Treatment Market Size by Region (2020-2031)
  • 2.3 Hyperinsulinemia Hypoglycaemia Treatment Market Dynamics
    • 2.3.1 Hyperinsulinemia Hypoglycaemia Treatment Industry Trends
    • 2.3.2 Hyperinsulinemia Hypoglycaemia Treatment Market Drivers
    • 2.3.3 Hyperinsulinemia Hypoglycaemia Treatment Market Challenges
    • 2.3.4 Hyperinsulinemia Hypoglycaemia Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Revenue Hyperinsulinemia Hypoglycaemia Treatment by Players
    • 3.1.1 Global Hyperinsulinemia Hypoglycaemia Treatment Revenue by Players (2020-2025)
    • 3.1.2 Global Hyperinsulinemia Hypoglycaemia Treatment Revenue Market Share by Players (2020-2025)
  • 3.2 Global Hyperinsulinemia Hypoglycaemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Global Key Players of Hyperinsulinemia Hypoglycaemia Treatment, Ranking by Revenue, 2023 VS 2024 VS 2025
  • 3.4 Global Market Concentration Ratio
    • 3.4.1 Global Hyperinsulinemia Hypoglycaemia Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Hyperinsulinemia Hypoglycaemia Treatment Revenue in 2024
  • 3.5 Global Key Players of Hyperinsulinemia Hypoglycaemia Treatment Head office and Area Served
  • 3.6 Global Key Players of Hyperinsulinemia Hypoglycaemia Treatment, Product and Application
  • 3.7 Global Key Players of Hyperinsulinemia Hypoglycaemia Treatment, Date of Enter into This Industry
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type

  • 4.1 Global Hyperinsulinemia Hypoglycaemia Treatment Historic Market Size by Type (2020-2025)
  • 4.2 Global Hyperinsulinemia Hypoglycaemia Treatment Forecasted Market Size by Type (2026-2031)

5 Breakdown Data by Application

  • 5.1 Global Hyperinsulinemia Hypoglycaemia Treatment Historic Market Size by Application (2020-2025)
  • 5.2 Global Hyperinsulinemia Hypoglycaemia Treatment Forecasted Market Size by Application (2026-2031)

6 North America

  • 6.1 North America Hyperinsulinemia Hypoglycaemia Treatment Market Size (2020-2031)
  • 6.2 North America Market Size by Type
    • 6.2.1 North America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Type (2020-2031)
    • 6.2.2 North America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)
  • 6.3 North America Market Size by Application
    • 6.3.1 North America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Application (2020-2031)
    • 6.3.2 North America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)
  • 6.4 North America Market Size by Country
    • 6.4.1 North America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Country: 2020 VS 2024 VS 2031
    • 6.4.2 North America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Country (2020-2031)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Hyperinsulinemia Hypoglycaemia Treatment Market Size (2020-2031)
  • 7.2 Europe Market Size by Type
    • 7.2.1 Europe Hyperinsulinemia Hypoglycaemia Treatment Market Size by Type (2020-2031)
    • 7.2.2 Europe Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)
  • 7.3 Europe Market Size by Application
    • 7.3.1 Europe Hyperinsulinemia Hypoglycaemia Treatment Market Size by Application (2020-2031)
    • 7.3.2 Europe Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)
  • 7.4 Europe Market Size by Country
    • 7.4.1 Europe Hyperinsulinemia Hypoglycaemia Treatment Market Size by Country: 2020 VS 2024 VS 2031
    • 7.4.2 Europe Hyperinsulinemia Hypoglycaemia Treatment Market Size by Country (2020-2025)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic Countries

8 China

  • 8.1 China Hyperinsulinemia Hypoglycaemia Treatment Market Size (2020-2031)
  • 8.2 China Market Size by Type
    • 8.2.1 China Hyperinsulinemia Hypoglycaemia Treatment Market Size by Type (2020-2031)
    • 8.2.2 China Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)
  • 8.3 China Market Size by Application
    • 8.3.1 China Hyperinsulinemia Hypoglycaemia Treatment Market Size by Application (2020-2031)
    • 8.3.2 China Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)

9 Asia (excluding China)

  • 9.1 Asia Hyperinsulinemia Hypoglycaemia Treatment Market Size (2020-2031)
  • 9.2 Asia Market Size by Type
    • 9.2.1 Asia Hyperinsulinemia Hypoglycaemia Treatment Market Size by Type (2020-2031)
    • 9.2.2 Asia Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)
  • 9.3 Asia Market Size by Application
    • 9.3.1 Asia Hyperinsulinemia Hypoglycaemia Treatment Market Size by Application (2020-2031)
    • 9.3.2 Asia Hyperinsulinemia Hypoglycaemia Treatment Market Share by Application (2020-2031)
  • 9.4 Asia Market Size by Region
    • 9.4.1 Asia Hyperinsulinemia Hypoglycaemia Treatment Market Size by Region: 2020 VS 2024 VS 2031
    • 9.4.2 Asia Hyperinsulinemia Hypoglycaemia Treatment Market Size by Region (2020-2031)
    • 9.4.3 Japan
    • 9.4.4 South Korea
    • 9.4.5 China Taiwan
    • 9.4.6 Southeast Asia
    • 9.4.7 India
    • 9.4.8 Australia

10 Middle East, Africa, and Latin America

  • 10.1 Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Size (2020-2031)
  • 10.2 Middle East, Africa, and Latin America Market Size by Type
    • 10.2.1 Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Type (2020-2031)
    • 10.2.2 Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Share by Type (2020-2031)
  • 10.3 Middle East, Africa, and Latin America Market Size by Application
    • 10.3.1 Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Application (2020-2031)
    • 10.3.2 Middle East, Africa, and Latin America Market Share by Application (2020-2031)
  • 10.4 Middle East, Africa, and Latin America Market Size by Country
    • 10.4.1 Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Country: 2020 VS 2024 VS 2031
    • 10.4.2 Middle East, Africa, and Latin America Hyperinsulinemia Hypoglycaemia Treatment Market Size by Country (2020-2031)
    • 10.4.3 Brazil
    • 10.4.4 Mexico
    • 10.4.5 Turkey
    • 10.4.6 Saudi Arabia
    • 10.4.7 Israel
    • 10.4.8 GCC Countries

11 Key Players Profiles

  • 11.1 Eli Lilly and Company
    • 11.1.1 Eli Lilly and Company Company Details
    • 11.1.2 Eli Lilly and Company Business Overview
    • 11.1.3 Eli Lilly and Company Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.1.4 Eli Lilly and Company Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.1.5 Eli Lilly and Company Recent Development
  • 11.2 Novo Nordisk A/S
    • 11.2.1 Novo Nordisk A/S Company Details
    • 11.2.2 Novo Nordisk A/S Business Overview
    • 11.2.3 Novo Nordisk A/S Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.2.4 Novo Nordisk A/S Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.2.5 Novo Nordisk A/S Recent Development
  • 11.3 Sanofi S.A.
    • 11.3.1 Sanofi S.A. Company Details
    • 11.3.2 Sanofi S.A. Business Overview
    • 11.3.3 Sanofi S.A. Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.3.4 Sanofi S.A. Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.3.5 Sanofi S.A. Recent Development
  • 11.4 Mallinckrodt Pharmaceuticals
    • 11.4.1 Mallinckrodt Pharmaceuticals Company Details
    • 11.4.2 Mallinckrodt Pharmaceuticals Business Overview
    • 11.4.3 Mallinckrodt Pharmaceuticals Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.4.4 Mallinckrodt Pharmaceuticals Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.4.5 Mallinckrodt Pharmaceuticals Recent Development
  • 11.5 Ipsen Pharma
    • 11.5.1 Ipsen Pharma Company Details
    • 11.5.2 Ipsen Pharma Business Overview
    • 11.5.3 Ipsen Pharma Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.5.4 Ipsen Pharma Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.5.5 Ipsen Pharma Recent Development
  • 11.6 Teva Pharmaceutical Industries Ltd.
    • 11.6.1 Teva Pharmaceutical Industries Ltd. Company Details
    • 11.6.2 Teva Pharmaceutical Industries Ltd. Business Overview
    • 11.6.3 Teva Pharmaceutical Industries Ltd. Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.6.4 Teva Pharmaceutical Industries Ltd. Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.6.5 Teva Pharmaceutical Industries Ltd. Recent Development
  • 11.7 Dr. Reddy's Laboratories Ltd.
    • 11.7.1 Dr. Reddy's Laboratories Ltd. Company Details
    • 11.7.2 Dr. Reddy's Laboratories Ltd. Business Overview
    • 11.7.3 Dr. Reddy's Laboratories Ltd. Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.7.4 Dr. Reddy's Laboratories Ltd. Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.7.5 Dr. Reddy's Laboratories Ltd. Recent Development
  • 11.8 Wockhardt Limited
    • 11.8.1 Wockhardt Limited Company Details
    • 11.8.2 Wockhardt Limited Business Overview
    • 11.8.3 Wockhardt Limited Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.8.4 Wockhardt Limited Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.8.5 Wockhardt Limited Recent Development
  • 11.9 Baxter International Inc.
    • 11.9.1 Baxter International Inc. Company Details
    • 11.9.2 Baxter International Inc. Business Overview
    • 11.9.3 Baxter International Inc. Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.9.4 Baxter International Inc. Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.9.5 Baxter International Inc. Recent Development
  • 11.10 Fresenius Kabi AG
    • 11.10.1 Fresenius Kabi AG Company Details
    • 11.10.2 Fresenius Kabi AG Business Overview
    • 11.10.3 Fresenius Kabi AG Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.10.4 Fresenius Kabi AG Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.10.5 Fresenius Kabi AG Recent Development
  • 11.11 Mylan N.V.
    • 11.11.1 Mylan N.V. Company Details
    • 11.11.2 Mylan N.V. Business Overview
    • 11.11.3 Mylan N.V. Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.11.4 Mylan N.V. Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.11.5 Mylan N.V. Recent Development
  • 11.12 Accord Healthcare Ltd.
    • 11.12.1 Accord Healthcare Ltd. Company Details
    • 11.12.2 Accord Healthcare Ltd. Business Overview
    • 11.12.3 Accord Healthcare Ltd. Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.12.4 Accord Healthcare Ltd. Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.12.5 Accord Healthcare Ltd. Recent Development
  • 11.13 Oramed Pharmaceuticals Inc.
    • 11.13.1 Oramed Pharmaceuticals Inc. Company Details
    • 11.13.2 Oramed Pharmaceuticals Inc. Business Overview
    • 11.13.3 Oramed Pharmaceuticals Inc. Hyperinsulinemia Hypoglycaemia Treatment Introduction
    • 11.13.4 Oramed Pharmaceuticals Inc. Revenue in Hyperinsulinemia Hypoglycaemia Treatment Business (2020-2025)
    • 11.13.5 Oramed Pharmaceuticals Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
      • 13.1.1.1 Research Programs/Design
      • 13.1.1.2 Market Size Estimation
      • 13.1.1.3 Market Breakdown and Data Triangulation
    • 13.1.2 Data Source
      • 13.1.2.1 Secondary Sources
      • 13.1.2.2 Primary Sources
  • 13.2 Author Details
  • 13.3 Disclaimer